The Biden Justice Department relaxed its policies on intercepting fentanyl amid an internal investigation into an operation that allegedly permitted hundreds of thousands of fentanyl pills to enter communities in New Mexico. This policy shift came while reviewing a whistleblower complaint accusing federal officials of intentionally allowing the dangerous drug to flow onto U.S. streets to track major traffickers.
During the Trump administration, the Justice Department had established strict rules in 2019 requiring agents involved in wiretap investigations to take “reasonable efforts to prevent the distribution” of fentanyl, even if it complicated ongoing cases. However, in 2024, the Biden Justice Department amended these guidelines, granting investigators discretion in deciding whether to intervene to stop fentanyl trafficking.
This change arose shortly after a whistleblower complaint filed in late 2023 by a Drug Enforcement Administration special agent highlighted concern that federal agents in New Mexico were instructed to allow fentanyl shipments to pass unseized. The complaint alleged the U.S. attorney’s office directed agents not to confiscate the pills, sparking fears the drugs spread beyond New Mexico and into other parts of the country.
The policy revision allowing discretion over fentanyl seizures has drawn criticism from whistleblower advocates, who argued it was a strategic move by the Justice Department to mitigate fallout from the complaint. One advocacy group representing the whistleblower suggested the adjustment either acknowledged a pre-existing plan to change tactics or responded to local federal officials’ pressure to permit the drug’s movement for investigative purposes.
Federal and state authorities have since launched investigations into the operation. The Justice Department’s Office of Inspector General is examining its handling of the case, while the New Mexico Attorney General is assessing whether any violations of state law occurred by allowing fentanyl to circulate.
The controversy centers on balancing the need to dismantle drug trafficking networks against the immediate public health risks posed by fentanyl entering communities. The 2019 protocol prioritized seizure to limit harm, but the revised policy under Biden places more weight on discretion aimed at apprehending higher-level drug figures even if it means short-term drug distribution.
Details from the whistleblower complaint revealed a potential conflict in federal enforcement priorities, raising questions about oversight and accountability in combating the fentanyl crisis. Given fentanyl’s lethality, the shift in Justice Department policy and its impact on enforcement operations continue to attract scrutiny.